Gmryl-M2 Tablet PR contains a combination of Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, enhancing glucose uptake and utilization. The combination provides complementary mechanisms to achieve better glycemic control in patients inadequately controlled on diet and exercise alone or on monotherapy. Gmryl-M2 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan including lifestyle modifications such as diet and physical activity. It is important to monitor blood glucose levels regularly to adjust dosage and prevent hypoglycemia, a potential adverse effect associated with sulfonylureas. Metformin is generally well-tolerated but may cause gastrointestinal disturbances and, rarely, lactic acidosis in predisposed individuals. Contraindications include severe renal or hepatic impairment, acute metabolic acidosis, and hypersensitivity to components. Patients should be advised on adherence, potential side effects, and the importance of regular follow-up. Gmryl-M2 Tablet PR should be used under medical supervision to optimize therapeutic outcomes and minimize risks.

Dosage & How to Use